Cox, Johnson, and Alexander (2012) report cochlear dead regions (DRs) occur when inner hair cells at a given frequency are lost or malfunctioning. Previous publications have suggested hearing-aid high-frequency gain should be attenuated in the presence of high frequency DRs.
Precondition for a VdS approval procedure, among others, is proof of a certified quality management system in accordance with DIN EN ISO 9001 for the manufacturing facility of the product.
Fisking Provectus' Claims About PV-10's FDA Approval Path. Another update to the Provectus PV-10 melanoma drug story. Provectus Biopharmaceuticals (PVCT: Pink Sheets) now says it will submit data from its phase II study of the melanoma drug PV-10 to the FDA, seeking breakthrough therapy designation (BTD), as expected.